Key Points • iFCR followed by 2 years of ibrutinib maintenance led to sustained deep remission in CLL irrespective of immunoglobulin heavy-chain variable region gene status.• Recurrent CLL lacked BTK… Click to show full abstract
Key Points • iFCR followed by 2 years of ibrutinib maintenance led to sustained deep remission in CLL irrespective of immunoglobulin heavy-chain variable region gene status.• Recurrent CLL lacked BTK mutations and retained sensitivity to ibrutinib upon retreatment.
Keywords:
phase study;
year follow;
cll;
five year;
follow phase;
study ibrutinib
Journal Title: Blood Advances
Year Published: 2024
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Blood Advances
Year Published: 2024
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!